Jounce Therapeutics CEO and leadership

Rich has over 20 years of R&D experience involving the immune system and cancer. He has established and operated protein therapeutic efforts in start-up as well as large pharmaceutical companies.

Dmitri Wiederschain, Ph.D., brings to Jounce more than 15 years of pharmaceutical industry experience as a scientific leader and drug developer. Dr. Wiederschain joins Jounce from Sanofi, where he held roles of increasing responsibility over the course of 11 years and helped build a pipeline encompassing a diverse array of immuno-oncology approaches. Most recently, he was vice president and global head of immuno-oncology research where he oversaw projects from conception to IND stage, built productive partnerships and research collaborations and advanced 10 development candidates into the clinic while leading a large international team of scientists in both the U.S. and France. Prior to joining Sanofi, Dr. Wiederschain was an investigator and laboratory head of discovery biology, and prior to that a presidential post-doctoral fellow in oncology at Novartis Institutes for Biomedical Research. He has co-authored 45 publications in peer-reviewed journals to date.

Dr. Wiederschain holds a Ph.D. in Biological Sciences and an A.L.B. in Natural Sciences from Harvard University.

Rich has over 20 years of R&D experience involving the immune system and cancer. He has established and operated protein therapeutic efforts in start-up as well as large pharmaceutical companies.